Zhongsheng Pharmaceutical (002317.SZ) subsidiary's innovative drug Angla Diwei granules phase II clinical trial obtained top-line analysis data results.

Zhizhong Finance and Economics APP news, Zhongsheng Pharmaceutical (002317.SZ) announced that its controlling subsidiary Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (hereinafter referred to as "Zhongsheng Ruichuang") independently developed an innovative drug called Angleludeweigranules (code-named ZSP1273 granules) for the treatment of 2-17-year-old patients with pure type A influenza. Phase II clinical trial data was recently obtained. Preliminary results show that Angleludeweigranules demonstrated positive efficacy and good safety in participants aged 2-17 with pure type A influenza, with trial results meeting expectations and achieving the intended purpose.